| abstract |
The present invention provides a method for manufacturing a medicament intended for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and oxaliplatin is used, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and oxaliplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practising this invention is the compound erlotinib HCl (also known as TarcevaTM). |